Ibrutinib not checked
Johnson & Johnson (Janssen) · JNJ-54179060 · PCI-32765
FollowEvery change as it happens, and a Monday email
Trials
21 active
26 in total · 25 in the EU
Targets
—
None known yet
What this is
- How it works
- Blocks BTK, an enzyme B cells (a type of immune cell) need to grow and work. Used against some blood cancers and immune diseases.BTK inhibitor Named by hand
- How it’s given
- “Participants will receive ibrutinib 420 mg orally once daily until disease progression or unacceptable toxicity during the subsequent therapy phase.”In the company’s words, NCT03462719 on ClinicalTrials.gov
- Tested for
- Leukemia, Lymphocytic, Chronic, B-Cell (3 trials), Small Lymphocytic Lymphoma (2 trials), Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease and 6 more
- Main trialPhase 3
- “The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).”In the company’s words, NCT03462719 on ClinicalTrials.gov
- Other names
- JNJ-54179060 · PCI-32765
Other drugs for Leukemia, Lymphocytic, Chronic, B-Cell
- SonrotoclaxBeOne Medicines (BeiGene) · Phase 3
- VenetoclaxAbbVie · Phase 3
- ZanubrutinibBeOne Medicines (BeiGene) · Phase 3
- TacabrutidegBeOne Medicines (BeiGene) · Phase 3
- AcalabrutinibAstraZeneca · Phase 3
- NemtabrutinibMerck & Co. · Phase 3
Coming up3
- 31 DecPhase 3 trial completes · ClinicalTrials.gov
- 15 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- 19 Jan 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials26
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 26 Feb 2021 | A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | |
| Phase 3Active, not recruiting | 31 Dec 2026 | A Long-term Extension Study of PCI-32765 (Ibrutinib) | |
| Phase 2Active, not recruiting | 15 Dec 2027 | A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia | |
| Phase 1Enrolling by invitation | 19 Jan 2028 | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring | |
| Phase 3Completed | 30 May 2022 | A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma | |
| Phase 3Authorised | not given | A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17 | |
| Phase 2Authorised | not given | Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia - A MULTICENTER OPEN LABEL, SINGLE ARM EUROPEAN PHASE II STUDY (ECWM-2) | |
| Phase 2Authorised | not given | Venetoclax in combination with the BTK inhibitor Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with treatment naive Mantle Cell Lymphoma not eligible for high dose therapy | |
| Phase 2Authorised | not given | Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B) | |
| Phase 2Authorised | not given | HOVON 158 CLL: First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in complete remission and/or with detectable bone marrow minimal residual disease (NEXT STEP trial) | |
| Phase 2Expired | not given | A Phase II study evaluating efficacy of KTE-X19 CAR-T cell therapy in Relapsed or Refractory Mantle-Cell Lymphoma achieving a partial response during Ibrutinib salvage therapy | |
| Phase 2Authorised | not given | MALIBU trial - Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas | |
| Phase 2Authorised | not given | Ibrutinib for the Treatment of Autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or CLL-like monoclonal B-cell lymphocytosis. CLL2323 | |
| Phase 2Ended | not given | HOVON 141 CLL: A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations. | |
| Phase 3Ended | not given | TRIANGLE - autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European mcl network trial | |
| Phase 2Authorised | not given | Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance in untreated patients with Activated-B-Cell (ABC)-DLBCL at intermediate-high and high risk (IPI ≥2) | |
| Phase 2Authorised | not given | Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) | |
| Phase 2Authorised | not given | Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinical forms of Mantle Cell Lymphoma. | |
| Phase 1/2Authorised | not given | OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma | |
| Phase 2/3Authorised | not given | ENRICH - Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma | |
| Phase 2Authorised | not given | Clonal evolution in progressive CLL patients harboring subclonal TP53 aberrations treated with ibrutinib first-line | |
| Phase 2Authorised | not given | Fixed-duration therapy with ibrutinib and obinutuzumab (GA-101) in treatment-naïve patients with CLL | |
| Phase 1/2Ended | not given | A phase I/II trial of Obinutuzumab, ABT-199 (GDC-0199) plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma patients (OAsIs) | |
| Phase 2Authorised | not given | EVITA - Epcoritamab plus Venetoclax plus Ibrutinib in patients with chronic lymphocytic leukemia with TP53 Alterations | |
| Phase 4Authorised | not given | A multicentre, adaptive, randomised, multidomain, platform trial for dose optimization in the treatment of adult patients with haematological diseases (BLOOD-dose): core protocol | |
| Phase 2Authorised | not given | HOVON 185: Pharmacokinetic boosting of ibrutinib with ritonavir in patients with chronic lymphocytic leukemia, lymphoplasmacytic- and mantle cell lymphoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026